Davide Prandi
Davide Prandi
Verified email at
Cited by
Cited by
The molecular taxonomy of primary prostate cancer
A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ...
Cell 163 (4), 1011-1025, 2015
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
H Beltran, D Prandi, JM Mosquera, M Benelli, L Puca, J Cyrta, C Marotz, ...
Nature medicine 22 (3), 298-305, 2016
Punctuated evolution of prostate cancer genomes
SC Baca, D Prandi, MS Lawrence, JM Mosquera, A Romanel, Y Drier, ...
Cell 153 (3), 666-677, 2013
Genomic correlates of clinical outcome in advanced prostate cancer
W Abida, J Cyrta, G Heller, D Prandi, J Armenia, I Coleman, M Cieslik, ...
Proceedings of the National Academy of Sciences 116 (23), 11428-11436, 2019
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
P Mu, Z Zhang, M Benelli, WR Karthaus, E Hoover, CC Chen, ...
Science 355 (6320), 84-88, 2017
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
C Pauli, BD Hopkins, D Prandi, R Shaw, T Fedrizzi, A Sboner, V Sailer, ...
Cancer discovery 7 (5), 462-477, 2017
A highly specific SpCas9 variant is identified by in vivo screening in yeast
A Casini, M Olivieri, G Petris, C Montagna, G Reginato, G Maule, ...
Nature biotechnology 36 (3), 265-271, 2018
Tumor clone dynamics in lethal prostate cancer
S Carreira, A Romanel, J Goodall, E Grist, R Ferraldeschi, S Miranda, ...
Science translational medicine 6 (254), 254ra125-254ra125, 2014
Whole-exome sequencing of metastatic cancer and biomarkers of treatment response
H Beltran, K Eng, JM Mosquera, A Sigaras, A Romanel, H Rennert, ...
JAMA oncology 1 (4), 466-474, 2015
Patient derived organoids to model rare prostate cancer phenotypes
L Puca, R Bareja, D Prandi, R Shaw, M Benelli, WR Karthaus, J Hess, ...
Nature communications 9 (1), 2404, 2018
Clonal evolution of chemotherapy-resistant urothelial carcinoma
BM Faltas, D Prandi, ST Tagawa, AM Molina, DM Nanus, C Sternberg, ...
Nature genetics 48 (12), 1490-1499, 2016
A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers
H Beltran, C Oromendia, DC Danila, B Montgomery, C Hoimes, ...
Clinical Cancer Research 25 (1), 43-51, 2019
SPOP mutation leads to genomic instability in prostate cancer
G Boysen, CE Barbieri, D Prandi, M Blattner, SS Chae, A Dahija, ...
Elife 4, e09207, 2015
GPU computing for systems biology
L Dematté, D Prandi
Briefings in bioinformatics 11 (3), 323-333, 2010
Unraveling the clonal hierarchy of somatic genomic aberrations
D Prandi, SC Baca, A Romanel, CE Barbieri, JM Mosquera, J Fontugne, ...
Genome biology 15, 1-16, 2014
Hit and go CAS9 delivered through a lentiviral based self-limiting circuit
G Petris, A Casini, C Montagna, F Lorenzin, D Prandi, A Romanel, ...
Nature communications 8 (1), 15334, 2017
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity
J Cyrta, A Augspach, MR De Filippo, D Prandi, P Thienger, M Benelli, ...
Nature communications 11 (1), 5549, 2020
Beta-binders for biological quantitative experiments
P Degano, D Prandi, C Priami, P Quaglia
Electronic Notes in Theoretical Computer Science 164 (3), 101-117, 2006
Formal analysis of BPMN via a translation into COWS
D Prandi, P Quaglia, N Zannone
International Conference on Coordination Languages and Models, 249-263, 2008
ASEQ: fast allele-specific studies from next-generation sequencing data
A Romanel, S Lago, D Prandi, A Sboner, F Demichelis
BMC medical genomics 8, 1-12, 2015
The system can't perform the operation now. Try again later.
Articles 1–20